NCT05294328View on ClinicalTrials.gov

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

August 22, 2022

Study Completion Date

September 10, 2022

Conditions
PresbyopiaRefractive ErrorsEye Diseases
Interventions
DRUG

Aceclidine+Brimonidine combination ophthalmic solution

LNZ101-combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

LNZ100- aceclidine ophthalmic solution

DRUG

Vehicle Proprietary Ophthalmic Solution

Proprietary Vehicle Ophthalmic Solution

Trial Locations (5)

38119

INSIGHT-1 Study Site #2, Memphis

46240

INSIGHT-1 Study Site #3, Indianapolis

77027

INSIGHT-1 Study Site #5, Houston

91204

INSIGHT-1 Study Site #4, Glendale

01810

INSIGHT-1 Study Site #1, Andover

Sponsors
All Listed Sponsors
lead

LENZ Therapeutics, Inc

OTHER

NCT05294328 - Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia | Biotech Hunter | Biotech Hunter